ATE269699T1 - Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe - Google Patents

Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe

Info

Publication number
ATE269699T1
ATE269699T1 AT98967012T AT98967012T ATE269699T1 AT E269699 T1 ATE269699 T1 AT E269699T1 AT 98967012 T AT98967012 T AT 98967012T AT 98967012 T AT98967012 T AT 98967012T AT E269699 T1 ATE269699 T1 AT E269699T1
Authority
AT
Austria
Prior art keywords
adipose tissue
tissue
angiogenesis inhibitors
growth
endometriosis
Prior art date
Application number
AT98967012T
Other languages
English (en)
Inventor
Maria Rupnick
Robert S Langer
Judah Folkman
Original Assignee
Childrens Medical Center
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Massachusetts Inst Technology filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE269699T1 publication Critical patent/ATE269699T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/484Plasmin (3.4.21.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT98967012T 1997-10-31 1998-10-30 Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe ATE269699T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6444597P 1997-10-31 1997-10-31
PCT/US1998/022998 WO1999039702A2 (en) 1997-10-31 1998-10-30 Method for regulating size and growth of vascularized normal tissue

Publications (1)

Publication Number Publication Date
ATE269699T1 true ATE269699T1 (de) 2004-07-15

Family

ID=22056030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98967012T ATE269699T1 (de) 1997-10-31 1998-10-30 Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe

Country Status (9)

Country Link
US (1) US6306819B1 (de)
EP (1) EP1024801B1 (de)
JP (2) JP2002502814A (de)
AT (1) ATE269699T1 (de)
AU (1) AU3352799A (de)
CA (1) CA2307792C (de)
DE (1) DE69824750T2 (de)
ES (1) ES2224465T3 (de)
WO (1) WO1999039702A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001285919B2 (en) 2000-09-05 2007-08-23 Jiangsu Simcere Pharmaceutical R&D Co., Ltd Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
CA2445969A1 (en) * 2001-04-30 2002-11-07 Cell Genesys, Inc. Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins
WO2003057235A2 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
US7790670B2 (en) 2002-03-01 2010-09-07 Glanbia Nutritionals (Ireland) Ltd. Compositions and methods for treatment of body weight conditions
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CA2537236A1 (en) * 2003-08-29 2005-05-12 Children's Medical Center Corporation Anti-angiogenic peptides for treating or preventing endometriosis
US20070172474A1 (en) * 2004-04-02 2007-07-26 University Of Tennessee Research Foundiation Dairy components effective for fat loss
KR20080007450A (ko) * 2005-04-11 2008-01-21 유니버시티 오브 테네시 리서치 파운데이션 지방 감소에 효과적인 안정된 유제품 성분
WO2009021104A2 (en) * 2007-08-08 2009-02-12 Cavanaugh Brian J Method and apparatus for delivery of a ligating suture
CN102123586A (zh) * 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US20120010259A1 (en) * 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
CN102639494B (zh) 2009-10-09 2016-11-09 扎夫根公司 砜化合物及其制备和使用方法
US8772333B2 (en) 2010-01-08 2014-07-08 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
JP5913310B2 (ja) 2010-07-22 2016-04-27 ザフゲン,インコーポレイテッド 三環式化合物ならびにその作製および使用方法
CN103347870A (zh) 2010-11-09 2013-10-09 扎夫根股份有限公司 Metap-2抑制剂的结晶固体及其制备和使用方法
WO2012075020A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX342257B (es) * 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
KR20140053013A (ko) 2011-05-06 2014-05-07 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
EP2763671A2 (de) 2011-10-03 2014-08-13 Zafgen, Inc. Verfahren zur behandlung von altersbedingten erkrankungen
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
EP2804866B1 (de) 2012-01-18 2016-11-16 Zafgen, Inc. Tricyclische sulfonamidverbindungen sowie verfahren zur herstellung und verwendung davon
EP2847176A1 (de) 2012-05-07 2015-03-18 Zafgen, Inc. Polymorphes salz des oxalatsalzes von 6-o-(4-dimethylaminoethoxy-)cinnarnoyl-fumagillol und verfahren zur herstellung und verwendung davon
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
JP2015536983A (ja) 2012-11-05 2015-12-24 ザフゲン,インコーポレイテッド 肥満の治療及び抑制における三環式化合物の使用
AU2013337287B2 (en) 2012-11-05 2017-03-23 Zafgen, Inc. Methods of treating liver diseases
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
EA033912B1 (ru) 2013-04-10 2019-12-09 Синдевркс, Инк. ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ
CA3003760A1 (en) * 2014-11-03 2016-05-12 Tsinghua University Drug for inhibiting adipose cell differentiation and insulin resistance
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CA3005450A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
EP3870231A1 (de) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarker von metap2-inhibitoren und anwendungen davon
CN116635060A (zh) * 2020-10-23 2023-08-22 Sk生物科学株式会社 包含编码外来抗原的遗传物质的用于减小靶组织的尺寸或体积的疫苗组合物或药盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02289532A (ja) * 1989-02-27 1990-11-29 Takeda Chem Ind Ltd 生理活性物質tan―1085,そのアグリコン,製造法及び用途
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
EP0721781B1 (de) * 1994-12-15 2002-03-06 Advance Biofactures Of Curacao N.V. Verminderung des Fettgewebes durch Verwendung von Kollagenase
JPH1029940A (ja) * 1996-07-15 1998-02-03 Kureha Chem Ind Co Ltd エボジアミン誘導体含有hsp47合成抑制剤
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
DE19631806A1 (de) * 1996-08-07 1998-02-12 Wella Ag Sauerstoffschaum zur oxidativen Haarbehandlung
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CA2291514C (en) * 1997-05-30 2011-07-12 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
US6306819B1 (en) 2001-10-23
JP2011026332A (ja) 2011-02-10
CA2307792A1 (en) 1999-08-12
JP2002502814A (ja) 2002-01-29
WO1999039702A3 (en) 1999-10-14
CA2307792C (en) 2007-06-26
DE69824750T2 (de) 2005-07-07
ES2224465T3 (es) 2005-03-01
WO1999039702A2 (en) 1999-08-12
AU3352799A (en) 1999-08-23
EP1024801A2 (de) 2000-08-09
DE69824750D1 (de) 2004-07-29
EP1024801B1 (de) 2004-06-23

Similar Documents

Publication Publication Date Title
ATE269699T1 (de) Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
Gorski et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
Liu et al. Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies
Tammela Endocrine treatment of prostate cancer
Olive et al. New medical treatments for endometriosis
di Sant’Agnese Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments
NO20084148L (no) Fremgangsmåte og inretning for behandling av mikroskopiske rester av tumorer som er igjen i vev etter kirurgisk fjerning
Garnick Hormonal therapy in the management of prostate cancer: from Huggins to the present
Choi et al. Nitric oxide and tumor necrosis factor-α production by oleanolic acid via nuclear factor-κB activation in macrophages
RU2009113038A (ru) Комбинированная лекарственная терапия для лечения ожирения
WO2001051604A3 (en) Methods for identifying anti-cancer drug targets
MXPA02009745A (es) Producto de combinacion que comprende una antiandrogeno no-esteroidal y un inhibidor de quinasa tirosina rfce.
DE69427830D1 (de) Keime von kobalt-palladium zur thermischen behandlung von tumoren
JP2003525906A5 (de)
Chen et al. Role of Akt/protein kinase B in the activity of transcriptional coactivator p300
NO974943L (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
Levy et al. Effect of arginine on tumor growth in rats
BARKER Cofactor induced synthesis of D-glucose-6-phosphate: NADP oxidoreductase in the uterus
Pollard et al. Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model
Wolf The molecular mechanism of the stimulaton of adipocyte differentiation by a glucocorticoid
Mariani et al. Postmenopausal endometrial hyperplasia: role of danazol therapy
Gordillo et al. [36] Hemangioma model for in vivo angiogenesis: Inducible oxidative stress and MCP-1 expression in EOMA Cells
Yoshiji et al. Stimulatory effect of endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpression on type IV collagen and laminin gene expression in rat mammary carcinoma cells
DE60121980D1 (de) Verwendung von 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-on zur herstellung eines medikaments zur behandlung von brust-, eierstock-, endometrium-krebs, myelom und meningiom
Harding et al. Depression of alanine transaminase activity in the liver of rats bearing walker carcinoma 256

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties